Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 2/20 | 0.60 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.60 |
| ▸ | TRPC4 | Q9UBN4 | 1/20 | 0.60 |
| ▸ | TRPC5 | Q9UL62 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 6/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.59 |
| ▸ | TP53 | P04637 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 2/20 | 0.55 |
| ▸ | ALPG | P10696 | 2/20 | 0.55 |
| ▸ | PLAA | Q9Y263 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764617 | 0.91 | BCHE (0.65) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL8328333 | 0.84 | ALPL (0.64) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL21767293 | 0.83 | BCHE (0.58) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL7217251 | 0.81 | ALDH1A1 (0.48) | SMN1; SMN2CHRM1ALDH1A1MAPK1HSD17B10 | |
| SCHEMBL5845732 | 0.81 | BCHE (0.60) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL5844930 | 0.81 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL14638914 | 0.81 | BCHE (0.67) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL19501640 | 0.81 | MTOR (0.56) | RAB9ASMN1; SMN2TP53NPC1PKM | |
| SCHEMBL21767298 | 0.80 | BCHE (0.56) | BCHETRPC3TRPC4TRPC5RAB9A | |
| SCHEMBL5846138 | 0.79 | KCNH2 (0.60) | BCHETRPC3TRPC4TRPC5RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| WO-2023004308-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | INSPIRNA, INC. (US) | 2023-01-26 | — | — | WO | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3950673-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | Inspirna, Inc. (US) | 2022-02-09 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| EP-3137447-B1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX INC (US) | 2021-06-30 | — | — | EP | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | RGENIX, INC. (US) | 2020-07-21 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | INSPIRNA, INC. | 2017-02-23 | — | — | US | disclosed |
| WO-2016176636-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2016-11-03 | — | — | WO | disclosed |
| WO-2015168465-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | RGENIX, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| EP-0796855-B1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AG (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | WEHNER VOLKMAR (DE) | 2001-09-13 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
| EP-0796855-A1 | Inhibitors of bone resorption and vitronectin receptor antagonists | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240180912-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CREATINE TRANSPORT AS A TREATMENT FOR CANCER | KRAS, FOLR2, SLC19A1 | BCHE 2953/4885TRPC3 4553/4885TRPC4 4781/4885 |
| US-10717704-B2 | Inhibitors of creatine transport and uses thereof | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BCHE 1272/4885TRPC3 3751/4885TRPC4 4167/4885 |
| US-20170050924-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BCHE 1272/4885TRPC3 3751/4885TRPC4 4167/4885 |
| US-20190315680-A1 | INHIBITORS OF CREATINE TRANSPORT AND USES THEREOF | CKMT1A; CKMT1B, SLC25A1, SLC2A1 | BCHE 1272/4885TRPC3 3751/4885TRPC4 4167/4885 |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | BCHE 3759/4885TRPC3 843/4885TRPC4 622/4885 |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | BCHE 3759/4885TRPC3 843/4885TRPC4 622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.